IN FILAMENTOUS FUNGI	ONS FOR EXPRESSION OF RECOMBIN	
<ul> <li>☑ Utility Patent Application Transmittal</li> <li>☐ Design Patent Application Transmittal</li> <li>☐ Continuing Prosecution Application Request</li> <li>☐ Provisional Application Cover Sheet</li> <li>☐ Provisional Application Transmittal</li> <li>☐ Continuation/Divisional Application (Rule 1.53(b)) with copy of application</li> <li>☐ Request for Continued Examination INCLUDING:</li> <li>☒ Specification (pages 1 - 47)</li> <li>☒ Claims (claim(s) 1 - 35, 5 pgs.)</li> <li>☒ Drawings (Fig(s). 1 - 12, 18 pgs.)</li> </ul>	<ul> <li>Abstract of the Disclosure</li> <li>Executed Declaration/Power of Attorney</li> <li>Unexecuted Declaration/Power of Attorney</li> <li>Assignment/Assignment Recordation Form Cover Sheet (PTO-1595)</li> <li>Claim for Convention Priority w/_ certified copy(s)</li> <li>Preliminary Amendment</li> <li>Information Discl. Statement Transmittal Letter</li> <li>Information Disclosure Citation (PTO-1449)</li> <li>Information Disclosure Statement w/ 0 document(state)</li> <li>Petition for _ Month Extension of Time</li> <li>Constructive Petition for Extensions of Time</li> </ul>	□ Check for \$ 2,078.00 is enclosed     □ Check for \$ is enclosed     □ Charge \$ to Deposit Account     □ Sequence Listing in computer readable form and paper copy     □ Copy of International Search Report     □ Copy of International Preliminary Examination Report

PEST AVAILABLE COPY

031309-003



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CXC

In re Patent Application of

Heidi Sisniega Barroso et al.

Application No.: 09/647,543

Filing Date:

October 2, 2000

Group Art Unit: 1636

Examiner: Konstantina T Katcheves

Confirmation No.: 8353

Title: PROMOTER AND CONSTRUCTIONS FOR EXPRESSION OF RECOMBINANT PROTEINS IN

FILAMENTOUS FUNGI

## **AMENDMENT/REPLY TRANSMITTAL LETTER**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enc	losed is a reply for the above-identified patent application.			
X	A Petition for Extension of Time is also enclosed.			
	Terminal Disclaimer(s) and the \$\Bigsigmu\$			
X	Also enclosed is/are <u>1) Paper Copy of Sequence Listing; 2) Computer Readable Form (CRF) of Seq</u> Listing; 3) Copy of Date-Stamped Postcard dated October 2, 2000.			
	Small entity status is hereby claimed.			
	Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the \$395.00 (2801) ⋅ \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).			
	Applicant(s) requests that any previously unentered after final amendments <u>not</u> be entered. Continued examination is requested based on the enclosed documents identified above.			
	Applicant(s) previously submitted			
	on			
	for which continued examination is requested.			
	Applicant(s) requests suspension of action by the Office until at least which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.			
	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.			

Attorney Docket No. 031309-003

Application No. 09/647,543

X	No additional claim fee is required.
	An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS								
	No. of Claims	Highes of Cla Previo Paid	aims ously	Extra Claims		Ra	te	Additional Fee
Total Claims	61	MINUS	61 =	0	x	\$50.00	(1202) =	\$ 0.00
Independent Claims	9	MINUS	9 =	0	x	\$200.00	(1201) =	\$ 0.00
If Amendment adds m	ultiple depen	dent claim	s, add	\$360.00 (1203)				
Total Claim Amendme	ent Fee			· · · · · · · · · · · · · · · · · · ·				\$ 0.00
☐ Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee			\$ 0.00					
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT				\$ 0.00				

A check in the amount of	of	_ is enclosed for the fee due.
Charge	to Deposit Acc	ount No. 02-4800.
Charge	to credit card.	Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

**BUCHANAN INGERSOLL PC** 

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: November 2, 2005

Christopher L. North, Ph.D. Registration No. 50,433